Relmada Therapeutics (RLMD) Free Cash Flow (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Free Cash Flow for 15 consecutive years, with -$15.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 16.6% year-over-year to -$15.1 million; the TTM figure through Mar 2026 stood at -$42.8 million (up 24.65% YoY), while the FY2025 annual figure was -$45.8 million, up 11.53% from the prior year.
• Free Cash Flow slipped to -$15.1 million in Q1 2026 per RLMD's latest filing, from -$14.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$6.4 million in Q2 2025 and bottomed at -$35.9 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$15.8 million across 5 years, with a median of -$14.6 million in 2025.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 71.44% — and 2025, when it plunged 65.87%.
• Relmada Therapeutics' Free Cash Flow stood at -$35.9 million in 2022, then jumped by 71.44% to -$10.2 million in 2023, then rose by 14.15% to -$8.8 million in 2024, then tumbled by 65.87% to -$14.6 million in 2025, then retreated by 3.23% to -$15.1 million in 2026.
• Business Quant data shows RLMD's Free Cash Flow at -$15.1 million in Q1 2026, -$14.6 million in Q4 2025, and -$6.7 million in Q3 2025.